CDKN2D

Across TCGA pan-cancer cohorts, CDKN2D mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CDKN2D data layer compared with 23 for mass-spec protein.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher CDKN2D mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDKN2D expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

GBM, LUAD, and LSCC are the cancer types where CDKN2D mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.232	0.543	.002	10	view →
LUAD	DFS	Tertile	All	0.306	0.719	.023	4	view →
LSCC	DFS	Tertile	All	0.900	0.669	.034	1	view →
PDAC	OS	Tertile	All	1.000	0.651	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CDKN2D–GBM (DFS)

Open the GBM breakdown →